Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms.

Cruchaga C, Del-Aguila JL, Saef B, Black K, Fernandez MV, Budde J, Ibanez L, Deming Y, Kapoor M, Tosto G, Mayeux RP, Holtzman DM, Fagan AM, Morris JC, Bateman RJ, Goate AM; Dominantly Inherited Alzheimer Network (DIAN); Disease Neuroimaging Initiative (ADNI); NIA-LOAD family study, Harari O.

Alzheimers Dement. 2018 Feb;14(2):205-214. doi: 10.1016/j.jalz.2017.08.013. Epub 2017 Sep 21.

2.

Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease.

Chaudhury S, Patel T, Barber IS, Guetta-Baranes T, Brookes KJ, Chappell S, Turton J, Guerreiro R, Bras J, Hernandez D, Singleton A, Hardy J, Mann D; ARUK Consortium, Morgan K.

Neurobiol Aging. 2018 Feb;62:244.e1-244.e8. doi: 10.1016/j.neurobiolaging.2017.09.035. Epub 2017 Oct 10.

3.

PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.

Balasa M, Vidal-Piñeiro D, Lladó A, Antonell A, Bosch B, Castellanos F, Bargalló N, Bartres-Faz D, Molinuevo JL, Sánchez-Valle R.

J Alzheimers Dis. 2012;30(3):605-16. doi: 10.3233/JAD-2012-111949.

PMID:
22426017
4.

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.

Twohig D, Rodriguez-Vieitez E, Sando SB, Berge G, Lauridsen C, Møller I, Grøntvedt GR, Bråthen G, Patra K, Bu G, Benzinger TLS, Karch CM, Fagan A, Morris JC, Bateman RJ, Nordberg A, White LR, Nielsen HM; Dominantly Inherited Alzheimer Network (DIAN).

Acta Neuropathol Commun. 2018 Nov 26;6(1):130. doi: 10.1186/s40478-018-0624-z.

5.

Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.

Darst BF, Koscik RL, Racine AM, Oh JM, Krause RA, Carlsson CM, Zetterberg H, Blennow K, Christian BT, Bendlin BB, Okonkwo OC, Hogan KJ, Hermann BP, Sager MA, Asthana S, Johnson SC, Engelman CD.

J Alzheimers Dis. 2017;55(2):473-484.

6.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

7.

A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.

Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven C; BELNEU consortium.

Alzheimers Dement. 2015 Dec;11(12):1452-1460. doi: 10.1016/j.jalz.2015.02.013. Epub 2015 Jun 15.

8.

Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.

Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T, Kurkinen KM, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2015;43(2):565-73. doi: 10.3233/JAD-140777.

PMID:
25096612
9.

Polygenic risk scores in familial Alzheimer disease.

Tosto G, Bird TD, Tsuang D, Bennett DA, Boeve BF, Cruchaga C, Faber K, Foroud TM, Farlow M, Goate AM, Bertlesen S, Graff-Radford NR, Medrano M, Lantigua R, Manly J, Ottman R, Rosenberg R, Schaid DJ, Schupf N, Stern Y, Sweet RA, Mayeux R.

Neurology. 2017 Mar 21;88(12):1180-1186. doi: 10.1212/WNL.0000000000003734. Epub 2017 Feb 17.

10.

Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Alzheimer Disease Genetic Consortium (ADGC), Kauwe JS, Goate AM, Cruchaga C.

Acta Neuropathol. 2017 May;133(5):839-856. doi: 10.1007/s00401-017-1685-y. Epub 2017 Feb 28.

11.

Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.

Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.

J Alzheimers Dis. 2015;48(4):1043-50. doi: 10.3233/JAD-143018.

PMID:
26444752
12.

Assessing the presence of shared genetic architecture between Alzheimer's disease and major depressive disorder using genome-wide association data.

Gibson J, Russ TC, Adams MJ, Clarke TK, Howard DM, Hall LS, Fernandez-Pujals AM, Wigmore EM, Hayward C, Davies G, Murray AD, Smith BH, Porteous DJ, Deary IJ, McIntosh AM.

Transl Psychiatry. 2017 Apr 18;7(4):e1094. doi: 10.1038/tp.2017.49.

13.

Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.

Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.

J Alzheimers Dis. 2015;43(4):1393-402. doi: 10.3233/JAD-140339.

PMID:
25182737
14.

Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.

Voyle N, Patel H, Folarin A, Newhouse S, Johnston C, Visser PJ, Dobson RJ, Kiddle SJ; EDAR and DESCRIPA study groups and the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2017;55(4):1417-1427. doi: 10.3233/JAD-160707.

15.

Common polygenic variation enhances risk prediction for Alzheimer's disease.

Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N; GERAD/PERADES; IGAP consortia, Morgan K, Passmore P, Holmes C, Powell J, Brayne C, Gill M, Mead S, Goate A, Cruchaga C, Lambert JC, van Duijn C, Maier W, Ramirez A, Holmans P, Jones L, Hardy J, Seshadri S, Schellenberg GD, Amouyel P, Williams J.

Brain. 2015 Dec;138(Pt 12):3673-84. doi: 10.1093/brain/awv268. Epub 2015 Oct 21.

16.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
17.

Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease.

Mann DMA, Davidson YS, Robinson AC, Allen N, Hashimoto T, Richardson A, Jones M, Snowden JS, Pendleton N, Potier MC, Laquerrière A, Prasher V, Iwatsubo T, Strydom A.

Acta Neuropathol. 2018 Oct;136(4):569-587. doi: 10.1007/s00401-018-1866-3. Epub 2018 May 16.

18.

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels.

Maxwell TJ, Corcoran C, Del-Aguila JL, Budde JP, Deming Y, Cruchaga C, Goate AM, Kauwe JSK; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2018 Aug 28;10(1):86. doi: 10.1186/s13195-018-0410-y.

19.

The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels.

Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L.

Arch Gen Psychiatry. 2011 Feb;68(2):207-13. doi: 10.1001/archgenpsychiatry.2010.196.

PMID:
21300948
20.

Cardiorespiratory fitness alters the influence of a polygenic risk score on biomarkers of AD.

Schultz SA, Boots EA, Darst BF, Zetterberg H, Blennow K, Edwards DF, Koscik RL, Carlsson CM, Gallagher CL, Bendlin BB, Asthana S, Sager MA, Hogan KJ, Hermann BP, Cook DB, Johnson SC, Engelman CD, Okonkwo OC.

Neurology. 2017 Apr 25;88(17):1650-1658. doi: 10.1212/WNL.0000000000003862. Epub 2017 Mar 24.

Supplemental Content

Support Center